Non-hormonal systemic therapy in men with hormone-refractory prostate cancer and metastases: a systematic review from the Cancer Care Ontario Program in Evidence-based Care's Genitourinary Cancer Disease Site Group

BACKGROUND: Prostate cancer that has recurred after local therapy or disseminated distantly is usually treated with androgen deprivation therapy; however, most men will eventually experience disease progression within 12 to 20 months. New data emerging from randomized controlled trials (RCTs) of che...

Descripción completa

Detalles Bibliográficos
Autores principales: Winquist, Eric, Waldron, Tricia, Berry, Scott, Ernst, D Scott, Hotte, Sébastien, Lukka, Himu
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2006
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1550253/
https://www.ncbi.nlm.nih.gov/pubmed/16670021
http://dx.doi.org/10.1186/1471-2407-6-112

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1550253/
https://www.ncbi.nlm.nih.gov/pubmed/16670021
http://dx.doi.org/10.1186/1471-2407-6-112

Ejemplares similares